Thomas Waldmann, M.D.
Head, Cytokine Immunology and Immunotherapy Section
National Cancer Institute
9000 Rockville Pike
Building 10, Room 4N115
Bethesda, MD 20892
Dr. Waldmann received his M.D. from Harvard Medical School. He joined NCI in 1956 and has been chief of the Metabolism Branch since 1973. He studies the IL-2/IL-2 receptor system in growth of normal and neoplastic cells. He co-discovered IL-15 and introduced various forms of IL-2/IL-15R-directed therapy for leukemia and autoimmune diseases. He has initiated clinical trials employing this cytokine in the treatment of metastatic malignancy. His honors include the Ehrlich medal; the Stratton, Lila Gruber, Simon Shubitz, Milken, Artois-Baillet Latour, and Bristol-Myers Squibb prizes; AAI-Dana Foundation Award in Human Immunology Research; and election to the National Academy of Sciences, American Academy of Arts and Sciences, and Institute of Medicine, NAS.
Dr. Waldmann's Clinical Trial(s):
NCI's Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with leukemia, lymphoma, melanoma, and kidney cancer. Click on the trial(s) below for additional details, including a summary of primary eligibility, study outline, and information on how to contact the study team directly.